About Xenidate XL

Xenidate XL (methylphenidate hydrochloride) is a generic version of Concerta XL indicated as part of a comprehensive treatment programme for ADHD in children aged 6 years of age and over and adults when remedial measures alone prove insufficient.2

Demonstrated bioequivalence to Concerta XL

The biphasic release of Xenidate XL matches that of Concerta XL, giving patients similar release profile throughout their day and night.1

Adapted from Data on file Ref 10412

Fasting conditions1

A single-dose, randomised, open-label, two treatment, five-period, six-sequence crossover study comparing Xenidate XL 54 mg tablets to Concerta XL® 54 mg, which shows the mean plasma concentration of methylphenidate against time curves after administration of the test product and the reference product in 52 healthy subjects under fasting conditions and under fed conditions (in Fasting condition N=52, in Fed condition N=54).

Adapted from Data on file Ref 10412

Fed conditions1

A single-dose, randomised, open-label, two treatment, five-period, six-sequence crossover study comparing Xenidate XL 54 mg tablets to Concerta XL® 54 mg, which shows the mean plasma concentration of methylphenidate against time curves after administration of the test product and the reference product in 52 healthy subjects under fasting conditions and under fed conditions (in Fasting condition N=52, in Fed condition N=54).

Tolerability versus Concerta XL

Xenidate XL is a proven, high quality, interchangeable generic of its reference product, Concerta XL. Safety data published for Concerta XL may be extrapolated for the use of Xenidate XL.1 Very common (≥1/10) adverse effects include insomnia, nervousness and headache.2 For the full list of adverse events please consult the Xenidate XL Summary of Product Characteristics (SmPC) for each available dose.

UK-MET-2025-00005 October 2025